Updated August 6, 2026: Corrected the ANSM ban timeline (narcotics classifications of June 2023 and June 2024, not 2025), the date the 0.3% THC threshold took effect (January 2022), and the status of France’s medical cannabis programme, whose generalization decrees remained unpublished as of August 2026.

France 2026 CBD Rules: THC Limit, Banned Cannabinoids & Import Requirements

Yes — CBD is legal in France in 2026, but only if finished products contain no more than 0.3% total THC and contain no banned cannabinoids. France's ANSM has prohibited HHC, HHCPO, H4CBD, and THCP, and ingestible CBD still requires an authorized EU Novel Food dossier. Enforcement is led by ANSM and DGCCRF.

THC Threshold at 0.3%: EU Alignment and What It Means

Since the arrêté of December 30, 2021 took effect in January 2022, CBD products in France have been officially permitted to contain up to 0.3% total THC, an increase from the previous 0.2%. This harmonizes French law with EU regulations, creating more certainty for operators across the supply chain. However, the new threshold is a ceiling, not a goal: exceeding it—even marginally—risks product seizures and legal penalties. All products (including extracts, oils, e-liquids, and topicals) must comply with this limit at the point of sale and import.

• Importers: Lab certificates of analysis (COAs) are critical. These must be from accredited laboratories, include total THC measurement, and must be translated into French.
• Manufacturers & Distributors: Ongoing batch testing is a practical necessity. False or incomplete declarations invite enforcement from the DGCCRF (Direction générale de la concurrence, de la consommation et de la répression des fraudes).

New Bans: Neo‑Cannabinoids Are in the Crosshairs

France's National Agency for the Safety of Medicines (ANSM) issued sweeping bans in 2023 and 2024 on a range of synthetic and semi-synthetic cannabinoids—commonly dubbed neo‑cannabinoids. HHC, HHCO, and HHCP were classified as narcotics in June 2023, and an ANSM decision effective June 3, 2024 added HHCPO, H4CBD, H2CBD, THCP, and other hemisynthetic cannabinoids to the narcotics list. All remain banned in 2026.

Newer semi-synthetic molecules remain under active monitoring by the ANSM and at EU level. Enforcement is focused on:

• Products attempting to exploit regulatory gray zones
• Inaccurately labeled potency (especially misdeclared THC content)
• Products appealing to youth (colorful packaging, sweet flavors)
• Unauthorized therapeutic or wellness claims

For the latest ANSM actions and full list of banned cannabinoids, see the official press releases and industry reports.

Action Step for Operators

• Immediately audit product catalogs for any banned or high-risk cannabinoids—both as isolated ingredients and in blends.
• Cease distribution and advertising of products containing prohibited substances.
• Monitor emerging guidance by subscribing to ANSM and DGCCRF updates.

Import Requirements: Documentation, Safety, and Language

Importing CBD into France now requires stringent due diligence:

• COAs must be from a recognized, ISO-accredited laboratory, clearly stating total THC and screened for heavy metals, residual solvents, and pesticides.
• All certificates and technical documentation must be translated into French.
• Packaging and labeling must comply with French consumer safety laws, including ingredient listings, warnings, batch references, and legal addresses for consumer complaints.

Non-compliance—whether technical (missing language, incomplete COA) or substantive (THC overages, unproven claims)—risks border seizures, rapid market removals, and financial penalties. More at Essentia Pura.

Novel Food: The Gatekeeper for Ingestibles

Despite France's changes, the EU Novel Food regulation remains the primary gatekeeper for ingestible CBD products—oils, tinctures, drinks, gummies. As of August 2026, no CBD Novel Food application has been fully authorized (EFSA set a provisional safe intake level for CBD in late 2025, but authorizations remain pending), and enforcement actions persist. The DGCCRF, France's key food safety and fraud authority, will seize, restrict, or recall products for which the required Novel Food dossier has not been validated.

Takeaway for Importers & Brands:

• Verify every edible/ingestible product's Novel Food status. Without an authorized dossier, these SKUs are highly vulnerable to enforcement.
• Consider focusing on non-ingestible categories (topicals, cosmetics, e-liquids) for easier compliance—though these formats are not entirely risk-free.
• Stay updated on DGCCRF enforcement notices and rapid alert systems (see RASFF example).

Marketing, Advertising, and E‑Commerce: Avoiding Traps

Advertising CBD products in France must avoid therapeutic, wellness, or preventive health claims of any kind. The rules apply across all channels, but online and influencer marketing face additional scrutiny:

• Ads must be clearly targeted to adult audiences; platforms should implement robust age-gating.
• Influencer partnerships must disclose any paid promotion and avoid content likely to attract minors.
• Health claims (even indirect ones) can trigger immediate product delisting and potential sanctions. See influencer compliance best practices here.

E-commerce companies should:

• Implement clear, accessible channels for consumer complaints
• Prepare for undercover "test-buys" and product holds
• Provide updated privacy disclosures to align with cross-border transaction rules

Medical Cannabis Pilot: Transitioning to Wider Access

France's much-discussed medical cannabis experiment formally ended on December 31, 2024, with enrolled patients kept on treatment through a transitional phase. Generalization was authorized in principle by the 2024 Social Security Financing Act, but the implementing decrees had still not been published as of August 2026 (a draft decree on evaluation, reimbursement, and pricing was before the Conseil d'État in mid-2026). Once published, the decrees will determine:

• Approved qualifying conditions
• Product form factors (oils, capsules, dried flower, etc.)
• Compliance and recordkeeping expectations for pharmacies and doctors

Until full generalization takes effect, access remains limited to transitional-phase patients supplied through authorized channels. Marketing or distributing medical cannabis outside this pilot structure is illegal and harshly penalized (up to 5 years' imprisonment and substantial fines).

Stay alert for updates from Chambers Global Practice Guides and the French Ministry of Health.

Key Compliance Checklist for 2026

• Confirm all products are ≤ 0.3% total THC (with accredited, French-translated COAs by batch)
• Audit and immediately remove all banned/flagged cannabinoids (HHC, THCP, H4CBD, HHCPO, etc.)
• Relabel all packaging to French standards with appropriate warnings and legal contact details
• For ingestible products: check Novel Food status or limit SKUs to non-ingestible formats
• Monitor ANSM, DGCCRF, and RASFF for rapid enforcement alerts
• For online sales: robust age-gating, influencer vetting, complaint mechanisms, and readiness for mystery shopping/tests.

Stay compliant, stay informed! For real-time regulatory tracking, compliance checklists, and actionable guidance for the French market, turn to CannabisRegulations.ai.